Hostname: page-component-8448b6f56d-gtxcr Total loading time: 0 Render date: 2024-04-18T18:27:38.501Z Has data issue: false hasContentIssue false

Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia

Published online by Cambridge University Press:  23 September 2003

C. R. MACINTYRE
Affiliation:
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Children's Hospital at Westmead, Westmead, NSW, Australia, 2145
C. P. CHU
Affiliation:
University of Sydney Medical Program, Sydney, NSW, Australia
M. A. BURGESS
Affiliation:
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Children's Hospital at Westmead, Westmead, NSW, Australia, 2145
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The aims of the study were to compare the burden of varicella and herpes zoster in Australia. No national surveillance exists for varicella or herpes zoster. We used hospital morbidity data from 1993–9 and pharmaceutical prescribing data from 1995–9.

In the financial year 1998/99, there were 4718 hospitalizations for zoster compared to 1991 for varicella. For varicella the mean age of patients was 15 years compared to 69 years for zoster. The mean length of stay in hospital was 4·2 days for varicella and 12·7 days for zoster. Varicella accounted for 8396 (3726 with principal diagnosis varicella) bed days compared to 26266 (5382 with principal diagnosis of zoster) for zoster. The in-hospital case-fatality rate was 0·4% for varicella and 1% for zoster. In 1999, 59200 community-based cases of zoster were treated with antivirals. We estimate that 157266 cases of zoster occurred in the community in 1999, a rate of 830 per 100000 population.

Herpes zoster has a higher burden of disease than varicella, and must be a component of disease surveillance in order to determine the full impact of vaccination on the epidemiology of varicella zoster virus (VZV).

Type
Research Article
Copyright
© 2003 Cambridge University Press